Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL [Phase 2]
Phase II clinical trial evaluating the combination of ibrutinib and short-course fludarabine in treatment-naive chronic lymphocytic leukemia…
-
CLINICAL_TRIALS trial_result · 2020-09-25Clinical Trial Update: Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 trial evaluating the efficacy and safety of zanubrutinib in relapsed or refractory chronic lymphocytic leukemia and small lymphocy…
-
FDA approval · 2020-08-07FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 safety and tolerability study of PCI-32765 in various B-cell malignancies completed; results posted.
-
FDA approval · 2020-05-05FDA Approved: RITUXAN HYCELA — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Rituxan HYCELA (rituximab and hyaluronidase) from Genentech, expanding its approval through …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-04-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS trial_result · 2020-03-03Clinical Trial Update: A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 3]
Phase 3 trial evaluating ibrutinib with bendamustine and rituximab in relapsed/refractory CLL or SLL has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-02-24Clinical Trial Update: Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL [Phase 1, Phase 2]
A pilot study evaluating the Btk inhibitor PCI-32765 (ibrutinib) effects on leukemia cell kinetics and trafficking in CLL/SLL using heavy wa…
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi [Phase 2]
Phase 2 study evaluating safety and preliminary efficacy of tafasitamab with idelalisib or venetoclax in relapsed/refractory CLL/SLL patient…
-
CLINICAL_TRIALS trial_result · 2019-11-22Clinical Trial Update: Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies [Phase 2]
Phase 2 clinical trial assessing donor atorvastatin to prevent severe acute GVHD after nonmyeloablative peripheral blood stem cell transplan…
-
FDA approval · 2019-11-21FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) submitted by Cephalon, LLC.
-
CLINICAL_TRIALS trial_result · 2019-10-22Clinical Trial Update: Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma [Phase 2]
Phase 2 clinical trial of bortezomib, cladribine, and rituximab in advanced mantle cell lymphoma or indolent lymphoma has completed with res…
-
CLINICAL_TRIALS trial_result · 2019-10-11Clinical Trial Update: Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer [Phase 2]
Phase 2 clinical trial update on donor umbilical cord blood transplant for hematologic cancers; status completed with results posted.
-
FDA label_change · 2019-10-08FDA Approved: BENDEKA — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Bendeka (bendamustine hydrochloride) by Teva Pharmaceuticals to update its labeling.
-
CLINICAL_TRIALS trial_result · 2019-09-19Clinical Trial Update: Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL [Phase 1]
Phase 1 trial evaluating dimethylfumarate in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; study terminat…
-
CLINICAL_TRIALS trial_result · 2019-09-18Clinical Trial Update: Phase 2 Study of the Combination of Bruton's Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients [Phase 2]
Phase 2 trial evaluating the combination of PCI-32765 (ibrutinib) and rituximab in high-risk chronic lymphocytic leukemia and small lymphocy…
-
CLINICAL_TRIALS trial_result · 2019-09-17Clinical Trial Update: Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL [Phase 2]
Phase 2 trial evaluating ofatumumab-based induction chemoimmunotherapy in previously untreated chronic lymphocytic leukemia/small lymphocyti…
-
CLINICAL_TRIALS trial_result · 2019-09-06Clinical Trial Update: Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) [Phase 2]
Phase 2 trial investigating sapacitabine with cyclophosphamide and rituximab for relapsed CLL/SLL with 11q deletion; study terminated with r…
-
FDA approval · 2019-07-23FDA Approved: RUXIENCE — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved Ruxience (rituximab-pvvr) from Pfizer as a biosimilar to rituximab, under an original application; the approval covers multiple…
-
CLINICAL_TRIALS trial_result · 2019-07-11Clinical Trial Update: Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial evaluating fludarabine phosphate, radiation therapy, and rituximab followed by rituximab maintenance in high-risk chr…
-
CLINICAL_TRIALS trial_result · 2019-06-26Clinical Trial Update: Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL [Phase 2]
A phase 2 trial evaluating high-dose methylprednisone followed by ofatumumab and alemtuzumab in 17p deletion CLL/SLL has been terminated wit…
-
CLINICAL_TRIALS trial_result · 2019-05-29Clinical Trial Update: Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [Phase 2]
Phase 2 clinical trial evaluating autologous peripheral blood stem cell transplant followed by donor bone marrow transplant in high-risk B- …
-
FDA approval · 2019-05-23FDA Approved: TRUXIMA — Supplemental Application (Cephalon, Inc.)
FDA approved a supplemental application for TRUXIMA (rituximab-ABBS) submitted by Cephalon, Inc.
-
CLINICAL_TRIALS trial_result · 2019-05-21Clinical Trial Update: PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia [Phase 2]
Phase 2 results for Ibrutinib (PCI-32765) in relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, and B-cell pro…
-
CLINICAL_TRIALS trial_result · 2019-05-07Clinical Trial Update: Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating lenalidomide plus ofatumumab in previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma; comp…